Home / Intelligence /

Search

Webinars

Cracking the Code on Generative AI: From Hype to Impact

Available On Demand

Watched our AIML 101 webinar and ready to learn more? Trinity Life Sciences is excited to continue the conversation with our next webinar, which will dive deeper into how pharma companies can move beyond the hype to unlock the value of Generative AI (GenAI). Join Trinity experts, Steve Laux, VP of Commercial Insights & Advanced Analytics, Nabha Subramanya, VP of Data Science and Patrick Waring, Director of New Products & Strategy, as they sift through all the noise surrounding GenAI and share…

Watch Now

Webinars

Patient Finding with AIML: Increasing Targeting Precision and Field Force Pull Through

Available On Demand

There are four key pieces to Patient Finding: Identifying, collating and integrating the right data Defining the appropriate test population Building the right features in the model Planning and executing actions once you’ve found the patients All four are crucial to successfully find patients. Join Adrienne Lovink, Partner and Head of Real-World Evidence (RWE) at Trinity Life Sciences, as she hosts a lively discussion on the ins and outs of Patient Finding with Trinity panelists Steve Laux, Vice President of…

Watch Now

Blog

AIML-Based Patient Finding—Threading the Needle in the Haystack

Published July 21, 2023

For life sciences companies focused on rare diseases, accurate patient finding is a worthy challenge—one deserving dedicated time and resource to tackling and solving. The benefit of enrolling even one new patient is large, both for the lives of patients in need and the commercial success of the therapies. Why is patient finding in rare disease such a challenge? The hallmarks of a rare disease work against traditional targeting methods: small patient population sizes, complex disease recognition, lengthy roads to…

Read Now

Webinars

Artificial Intelligence & Machine Learning 101

Available On Demand

You have likely heard all the buzz around Artificial Intelligence and Machine Learning (AIML), but what does it really mean? It’s time to cut through the complexity during Trinity Life Sciences’ AIML 101 webinar. This webinar is designed for the AIML novice, who knows very little about the topic but doesn’t want to be left behind. AIML is here. Be ready with Trinity. Key Webinar Topics What is Artificial Intelligence? What is Machine Learning? Are they different? We’ll demystify how…

Watch Now

Webinars

Driving Commercial Success with AI: Build, Calibrate and Operationalize

Available On Demand

Now Available On Demand: In today’s cutthroat life sciences marketplace, commercial effectiveness in all its parts has never been so important.  From field force effectiveness to optimization of promotional investment through to Next Best Action implementation, tailoring the customer experience through content and tactics is the focus. Cross-functional coordination across teams and operationalizing at scale are the goal. Come join Nabha Subramanya, VP of Data Science at Trinity Life Sciences and Anushank Anand, Director in Trinity’s Analytics practice, as they…

Watch Now

Case Studies

Improving Targeting Precision and Field Force Direction through AIML-based Patient Finding

Background A global rare disease company was looking to improve targeting precision and support field team effectiveness Traditional targeting was non-viable due to the small size of the patient populations, complex disease recognition and diagnosis, and restrictive therapy eligibility criteria Attempts by a prior analytics partner to use rule-based alerts failed, and even after two years, no new patients had been identified Given the small number of patients in each indication, every new start is high value, both for the…

Read Now

Blog

AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway

Published September 27, 2021

Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies. The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based…

Read Now